JPWO2019126099A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019126099A5 JPWO2019126099A5 JP2020533679A JP2020533679A JPWO2019126099A5 JP WO2019126099 A5 JPWO2019126099 A5 JP WO2019126099A5 JP 2020533679 A JP2020533679 A JP 2020533679A JP 2020533679 A JP2020533679 A JP 2020533679A JP WO2019126099 A5 JPWO2019126099 A5 JP WO2019126099A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- carbonyl
- oxy
- methylisoxazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 57
- -1 cyano, hydroxyl Chemical group 0.000 claims 43
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 239000012453 solvate Substances 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000001188 haloalkyl group Chemical group 0.000 claims 16
- 125000004103 aminoalkyl group Chemical group 0.000 claims 12
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000003282 alkyl amino group Chemical group 0.000 claims 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 6
- SNGFDHSYZIJHLD-IFMALSPDSA-N CC1=NOC(=C1CNC(=O)OCC1=CC=CC=C1)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1 Chemical compound CC1=NOC(=C1CNC(=O)OCC1=CC=CC=C1)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1 SNGFDHSYZIJHLD-IFMALSPDSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- LCPOHKYHVWXVAB-RTBURBONSA-N (1R,3R)-3-[6-[3-methyl-4-(phenylmethoxycarbonylaminomethyl)-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C(=NOC=1C1=CC=C(C=N1)O[C@H]1C[C@@H](CCC1)C(=O)O)C LCPOHKYHVWXVAB-RTBURBONSA-N 0.000 claims 2
- LCPOHKYHVWXVAB-OALUTQOASA-N (1S,3S)-3-[6-[3-methyl-4-(phenylmethoxycarbonylaminomethyl)-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C(=NOC=1C1=CC=C(C=N1)O[C@@H]1C[C@H](CCC1)C(=O)O)C LCPOHKYHVWXVAB-OALUTQOASA-N 0.000 claims 2
- XMRFKPWOCTWKFR-OALUTQOASA-N (1S,3S)-3-[6-[4-[(benzylcarbamoylamino)methyl]-3-methyl-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound C(C1=CC=CC=C1)NC(NCC=1C(=NOC=1C1=CC=C(C=N1)O[C@@H]1C[C@H](CCC1)C(=O)O)C)=O XMRFKPWOCTWKFR-OALUTQOASA-N 0.000 claims 2
- JNQDBJBUKXSOCL-ROUUACIJSA-N (1S,3S)-3-[6-[4-[(hexoxycarbonylamino)methyl]-3-methyl-1,2-oxazol-5-yl]pyridin-3-yl]oxycyclohexane-1-carboxylic acid Chemical compound N1=C(C(=C(O1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(=O)O)C=N1)CNC(=O)OCCCCCC)C JNQDBJBUKXSOCL-ROUUACIJSA-N 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 2
- MXPOTZNIQKDAJE-ROUUACIJSA-N C(C1=CC=CC=C1)OC(=O)NCC=1C(=NOC=1C=1N=CC(=NC=1)O[C@@H]1C[C@H](CCC1)C(=O)O)C Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C(=NOC=1C=1N=CC(=NC=1)O[C@@H]1C[C@H](CCC1)C(=O)O)C MXPOTZNIQKDAJE-ROUUACIJSA-N 0.000 claims 2
- SSKOJIISJPDFTC-IRXDYDNUSA-N CC(C)COC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 Chemical compound CC(C)COC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 SSKOJIISJPDFTC-IRXDYDNUSA-N 0.000 claims 2
- ZCPYSXSSZYAHDU-HOTGVXAUSA-N CC(C)OC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 Chemical compound CC(C)OC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 ZCPYSXSSZYAHDU-HOTGVXAUSA-N 0.000 claims 2
- LJOQAPDTDHZMKT-RDJZCZTQSA-N CC1=NOC(=C1CNC(=O)OC1CCCC1)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CC1=NOC(=C1CNC(=O)OC1CCCC1)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 LJOQAPDTDHZMKT-RDJZCZTQSA-N 0.000 claims 2
- LQEDNATZZGDWHZ-IRXDYDNUSA-N CC1=NOC(=C1CNC(=O)OCC1CCC1)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CC1=NOC(=C1CNC(=O)OCC1CCC1)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 LQEDNATZZGDWHZ-IRXDYDNUSA-N 0.000 claims 2
- NEIDHRRNILCHGY-HKUYNNGSSA-N CC1=NOC(=C1CNC(=O)OCC2=CC(=CC=C2)F)C3=NC=C(C=C3)O[C@H]4CCC[C@@H](C4)C(=O)O Chemical compound CC1=NOC(=C1CNC(=O)OCC2=CC(=CC=C2)F)C3=NC=C(C=C3)O[C@H]4CCC[C@@H](C4)C(=O)O NEIDHRRNILCHGY-HKUYNNGSSA-N 0.000 claims 2
- ZVGQTCMOPXKQFC-RMNMTYGKSA-N CCC(C)COC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1 Chemical compound CCC(C)COC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1 ZVGQTCMOPXKQFC-RMNMTYGKSA-N 0.000 claims 2
- URAKHSBIESSZPC-ROUUACIJSA-N CCCCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 Chemical compound CCCCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 URAKHSBIESSZPC-ROUUACIJSA-N 0.000 claims 2
- DTYIXKBKWQYNPO-IRXDYDNUSA-N CCCCOC(=O)N(C)CC1=C(ON=C1C)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CCCCOC(=O)N(C)CC1=C(ON=C1C)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 DTYIXKBKWQYNPO-IRXDYDNUSA-N 0.000 claims 2
- LKQYVKHNPRKVHR-IRXDYDNUSA-N CCCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 Chemical compound CCCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 LKQYVKHNPRKVHR-IRXDYDNUSA-N 0.000 claims 2
- AGFGWFWGFCMHBI-HOTGVXAUSA-N CCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 Chemical compound CCCOC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C(C)=N1 AGFGWFWGFCMHBI-HOTGVXAUSA-N 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 2
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- YCWWEMOJCOTFEI-PIPMEXSNSA-N (1S,3R)-3-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(O[C@H]2C[C@H](CCC2)C(=O)O)C=C1 YCWWEMOJCOTFEI-PIPMEXSNSA-N 0.000 claims 1
- BPOGMEOTHLOVDS-DKSSEZFCSA-N (1S,3R)-3-[4-[4-[[(1R)-1-cyclopropylethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound C1(CC1)[C@@H](C)OC(=O)NC=1C(=NOC=1C1=CC=C(O[C@H]2C[C@H](CCC2)C(=O)O)C=C1)C BPOGMEOTHLOVDS-DKSSEZFCSA-N 0.000 claims 1
- YCWWEMOJCOTFEI-AGHHOFFYSA-N (1S,3S)-3-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound CC1=NOC(=C1NC(=O)O[C@H](C)C1=CC=CC=C1)C1=CC=C(O[C@@H]2C[C@H](CCC2)C(=O)O)C=C1 YCWWEMOJCOTFEI-AGHHOFFYSA-N 0.000 claims 1
- DDAPTNDJPXXEAV-ICSRJNTNSA-N (1S,3S)-3-[4-[4-[(3,3-dimethylbutoxycarbonylamino)methyl]-3-methyl-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound CC(CCOC(=O)NCC=1C(=NOC=1C1=CC=C(O[C@@H]2C[C@H](CCC2)C(=O)O)C=C1)C)(C)C DDAPTNDJPXXEAV-ICSRJNTNSA-N 0.000 claims 1
- BPOGMEOTHLOVDS-LJHODMEESA-N (1S,3S)-3-[4-[4-[[(1R)-1-cyclopropylethoxy]carbonylamino]-3-methyl-1,2-oxazol-5-yl]phenoxy]cyclohexane-1-carboxylic acid Chemical compound C1(CC1)[C@@H](C)OC(=O)NC=1C(=NOC=1C1=CC=C(O[C@@H]2C[C@H](CCC2)C(=O)O)C=C1)C BPOGMEOTHLOVDS-LJHODMEESA-N 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ROZCUVMFXOURIS-UHFFFAOYSA-N 2-phenylethanesulfonamide Chemical compound NS(=O)(=O)CCC1=CC=CC=C1 ROZCUVMFXOURIS-UHFFFAOYSA-N 0.000 claims 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- ZBGWJHMPXFGIIC-RMNMTYGKSA-N CC(OC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1)C1CC1 Chemical compound CC(OC(=O)NCC1=C(ON=C1C)C1=CC=C(O[C@@H]2CCC[C@H](C2)C(O)=O)C=C1)C1CC1 ZBGWJHMPXFGIIC-RMNMTYGKSA-N 0.000 claims 1
- KQABZYOUYWUYDT-UGKGYDQZSA-N CC1=NOC(=C1CNC(=O)OCC1=CC=C(Cl)C=C1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CC1=NOC(=C1CNC(=O)OCC1=CC=C(Cl)C=C1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 KQABZYOUYWUYDT-UGKGYDQZSA-N 0.000 claims 1
- WFXANVPKXBDTPO-UGKGYDQZSA-N CC1=NOC(=C1CNC(=O)OCC1=CC=CC(Cl)=C1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CC1=NOC(=C1CNC(=O)OCC1=CC=CC(Cl)=C1)C1=CC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 WFXANVPKXBDTPO-UGKGYDQZSA-N 0.000 claims 1
- ZJXLXWJELWCRMY-HOTGVXAUSA-N CCCCOC(=O)NCC1=C(ON=C1C)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 Chemical compound CCCCOC(=O)NCC1=C(ON=C1C)C1=NC=C(O[C@H]2CCC[C@@H](C2)C(O)=O)C=C1 ZJXLXWJELWCRMY-HOTGVXAUSA-N 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 206010072877 Intestinal fibrosis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 210000004207 dermis Anatomy 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 210000000232 gallbladder Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000002850 nasal mucosa Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- ABOYDMHGKWRPFD-UHFFFAOYSA-N phenylmethanesulfonamide Chemical compound NS(=O)(=O)CC1=CC=CC=C1 ABOYDMHGKWRPFD-UHFFFAOYSA-N 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607407P | 2017-12-19 | 2017-12-19 | |
| US62/607,407 | 2017-12-19 | ||
| PCT/US2018/066128 WO2019126099A1 (en) | 2017-12-19 | 2018-12-18 | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021507896A JP2021507896A (ja) | 2021-02-25 |
| JPWO2019126099A5 true JPWO2019126099A5 (enrdf_load_stackoverflow) | 2022-01-27 |
| JP7301840B2 JP7301840B2 (ja) | 2023-07-03 |
Family
ID=65003584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020533679A Active JP7301840B2 (ja) | 2017-12-19 | 2018-12-18 | Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11447475B2 (enrdf_load_stackoverflow) |
| EP (1) | EP3728210A1 (enrdf_load_stackoverflow) |
| JP (1) | JP7301840B2 (enrdf_load_stackoverflow) |
| KR (1) | KR102756637B1 (enrdf_load_stackoverflow) |
| CN (1) | CN112041304B (enrdf_load_stackoverflow) |
| WO (1) | WO2019126099A1 (enrdf_load_stackoverflow) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN112189010A (zh) | 2017-12-19 | 2021-01-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
| EP3852746B1 (en) | 2018-09-18 | 2023-03-29 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| JP7422788B2 (ja) | 2019-06-18 | 2024-01-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| WO2021116259A1 (en) | 2019-12-12 | 2021-06-17 | Chiesi Farmaceutici S.P.A. | Aromatic amido derivatives as lpa receptor 2 inhibitors |
| JP2023505702A (ja) | 2019-12-12 | 2023-02-10 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害剤としてのチエノピリミジン誘導体 |
| CN114786771A (zh) | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| JP2023533851A (ja) | 2020-07-16 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体阻害剤としてのアミドシクロヘキサン酸誘導体 |
| JP2023546742A (ja) * | 2020-10-22 | 2023-11-07 | ローツェ・バイオ・インコーポレイテッド | Ｌｐａ受容体活性に付随する症状を治療するための化合物および組成物 |
| WO2022100625A1 (zh) * | 2020-11-10 | 2022-05-19 | 武汉人福创新药物研发中心有限公司 | 氮取代氨基碳酸酯噻吩类化合物及其用途 |
| WO2022174882A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| WO2022174883A1 (en) | 2021-02-16 | 2022-08-25 | Chiesi Farmaceutici S.P.A. | 5-membered heterocyclyl derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors |
| JP2024512557A (ja) | 2021-03-24 | 2024-03-19 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ｌｐａ受容体２阻害物質としての８－シクロ－置換キナゾリン誘導体 |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US20250066341A1 (en) | 2021-12-23 | 2025-02-27 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| EP4490150A1 (en) | 2022-03-08 | 2025-01-15 | Chiesi Farmaceutici S.p.A. | Amido cyclopropyl derivatives as lpa receptor inhibitors |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137405D1 (de) | 2000-02-18 | 2009-03-05 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| JP4396808B2 (ja) | 2001-02-08 | 2010-01-13 | 小野薬品工業株式会社 | Ｌｐａ受容体調節剤からなる泌尿器疾患治療剤 |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) * | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CA2820817A1 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| CN103443098B (zh) | 2011-01-30 | 2016-03-16 | 广州源生医药科技有限公司 | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 |
| US9527807B2 (en) | 2011-04-05 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| WO2013070879A1 (en) * | 2011-11-10 | 2013-05-16 | Bristol-Myers Squibb Company | Methods for treating spinal cord injury with lpa receptor antagonists |
| WO2013085824A1 (en) | 2011-12-04 | 2013-06-13 | Angion Biomedica Corp. | Small molecule anti-fibrotic compounds and uses thereof |
| EA201492285A1 (ru) | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) |
| SG11201407228PA (en) | 2012-06-20 | 2014-12-30 | Hoffmann La Roche | N-aryltriazole compounds as lpar antagonists |
| US10000459B2 (en) * | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| JP2017095366A (ja) | 2015-11-18 | 2017-06-01 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| CN112189010A (zh) * | 2017-12-19 | 2021-01-05 | 百时美施贵宝公司 | 作为lpa拮抗剂的三唑n-连接的氨基甲酰基环己基酸 |
| KR102697358B1 (ko) * | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| EA202091500A1 (ru) * | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa |
| EP3728242B1 (en) * | 2017-12-19 | 2023-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
-
2018
- 2018-12-18 KR KR1020207020557A patent/KR102756637B1/ko active Active
- 2018-12-18 JP JP2020533679A patent/JP7301840B2/ja active Active
- 2018-12-18 EP EP18830685.6A patent/EP3728210A1/en active Pending
- 2018-12-18 WO PCT/US2018/066128 patent/WO2019126099A1/en not_active Ceased
- 2018-12-18 US US16/954,550 patent/US11447475B2/en active Active
- 2018-12-18 CN CN201880089219.XA patent/CN112041304B/zh active Active